VivoSeq
Oncology

Oral Cavity Cancer

20

Pipeline Programs↗

2

Active Trials↗

10

Companies Involved↗

Oral Cavity Cancer is an emerging landscape with 20 programs across 10 companies. The most active players are Mirati Therapeutics Inc., Brooklyn ImmunoTherapeutics, LLC, Alnylam Pharmaceuticals. 2 therapies are approved with 6 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

46/100

Pipeline Velocity

6/100

Mech. Concentration

20/100

Completion Rate

55/100

Attrition Rate

36/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Mirati Therapeutics Inc.

1 program

Phase 1B

Brooklyn ImmunoTherapeutics, LLC

1 program

Phase 1Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals

1 program

Phase 2Pfizer logo

Pfizer

1 program

Phase 2E

Eastern Cooperative Oncology Group

1 program

Phase 2M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

86%

Small molecule

18 of 21 classified programs — the dominant modality here.

14%ALL OTHERSMonoclonal antibody314%

Small molecule leads; the ring shows all 21 classified programs, each share of the total. Modality classified for 100% of 22 pipeline programs.

Analysis

Trial Status

14

clinical trials

Completed6 · 43%
Terminated3 · 21%
Withdrawn2 · 14%
Recruiting2 · 14%
Unknown status1 · 7%

Clinical Trials

Trial Activity

14 trials

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population
Recruiting·MMayo Clinic·Phase 2·NCT06997068·25 enrolled
Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery
Recruiting·UUniversity of Wisconsin, Madison·N/A·NCT07343596·20 enrolled
Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study
Completed·UUniversity Health Network, Toronto·Phase 1·NCT03575598·10 enrolled
CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer
Completed·TThe Clatterbridge Cancer Centre NHS Foundation Trust·Phase 2·NCT03721757·21 enrolled
A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients
Completed·—·Phase 1·NCT05590650·21 enrolled
Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer
Completed·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2/3·NCT02923258·224 enrolled
Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer
Completed·MMedical University of South Carolina·Phase 2·NCT03021993·17 enrolled
Study to Assess Biomarkers in Patients With Resectable Oral Cavity Cancer Randomized to Receive Preoperative Treatment
Completed·UUniversity Health Network, Toronto·Phase 1/2·NCT01116843·13 enrolled
Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer
Terminated·RRoswell Park Cancer Institute·Phase 1·NCT00670397·11 enrolled
A Study of High-Risk Oral Cavity Cancer
Terminated·National Health Research Institutes, Taiwan·Phase 2/3·NCT00934739·150 enrolled
Photodynamic Therapy With HPPH Compared to Standard of Care Surgery in Treating Patients With Oral Cavity Cancer
Terminated·RRoswell Park Cancer Institute·Phase 2·NCT03090412·2 enrolled
Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence
Withdrawn·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT01142414
Nivolumab & IRX-2 With Surgery for Resectable Stage III-IVA Oral Cavity Cancer or HPV-Positive Oropharyngeal Cancer
Withdrawn·EEmory University·Phase 1·NCT03575234
Maintenance Tegafur-uracil in Resected Oral Cavity Cancer With ECS+
Unknown status·—·Phase 2·NCT03121313·68 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)